Dr Spira on RMC-9805 in KRAS G12D–Mutated Pancreatic Ductal Adenocarcinoma

Alexander I. Spira MD, PhD, FACP, FASCO, codirector, Virginia Cancer Specialists Research Institute; director, Thoracic and Phase I Program, clinical assistant professor, Johns Hopkins, discusses data from a phase 1 study (NCT06040541) of RMC-9805 in previously treated, advanced 

 G12D–mutated solid tumors, including pancreatic ductal adenocarcinoma.

News

® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses. 

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Pancreatic Cancer

Gastrointestinal Cancers Symposium (ASCO GI)

Alexander I. Spira MD, PhD, FACP, FASCO, discusses data of RMC-9805 in previously treated, advanced KRAS G12D–mutated pancreatic ductal adenocarcinoma.